Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer.
A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe(3)O(4) with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 mug of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 degrees C and 37 degrees C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 degrees C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.
Hua
Mu-Yi
MY
Department of Chemical and Materials Engineering, Chang Gung University, Tao-Yuan, Taiwan, Republic of China.
Yang
Hung-Wei
HW
Chuang
Cheng-Keng
CK
Tsai
Rung-Ywan
RY
Chen
Wen-Jauh
WJ
Chuang
Kun-Lung
KL
Chang
Ying-Hsu
YH
Chuang
Heng-Chang
HC
Pang
See-Tong
ST
D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry* / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D008280:Magnetics; D008297:Male; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000737:chemistry* / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D017239:Paclitaxel